title: [Varenicline--a new drug for smoking cessation].
abstract: Varenicline is a new drug for smoking cessation that reduces cravings by binding to the alfa4-beta2-nicotine-achethylcholine receptors in the brain (partial agonist). Varenicline for 12 weeks was found to be effective for smoking cessation and more effective than bupropionSR after 3 months. The adverse events were mild with transient nausea reported by less than one third of the subjects. Varenicline should be used for smoking cessation when nicotine replacement products have failed or are undesired.
authors: Gentofte Hospital, Lungemedicinsk Afdeling, Hellerup. philipt@dadlnet.dk
authors: Philip
authors: P
authors: Tønnesen
mesh_terms: D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000378:metabolism; D016540:Smoking Cessation; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D000068580:Varenicline